TY -的T1 -回顾哮喘药物治疗:我们站在哪里,我们要去哪里?JF -欧洲呼吸杂志》乔和J - 10.1183/13993003.00700 -2023欧元SP - 2300700 AU -马里奥Cazzola AU -克莱夫·p页面AU -玛丽亚加布里埃尔马泰拉盟Paola Rogliani AU -尼古拉·a·Hanania Y1 2023/01/01 UR - //www.qdcxjkg.com/content/early/2023/06/29/13993003.00700 2023. -抽象N2 -一些当前的指导方针/战略大纲哮喘的治疗方法,它主要考虑的目标提高肺功能和生活质量和减少症状出现和加剧。他们建议加大或减少治疗的策略,根据当前哮喘症状病人的全面控制和未来恶化的风险。虽然这逐步方法无疑是实际的日常实践中,它并不总是解决这种异质性疾病的潜在机制。在过去的十年中,为了提高严重哮喘的治疗,如添加长效antimuscarinic代理传统ICS /腊八治疗,和引入疗法针对关键细胞因子。然而,尽管这些策略几个在这个人口仍未满足的需求,激励研究确定新的目标和发展改进治疗和/或预防哮喘治疗。等待这种治疗方法的可用性,有必要重新评估当前传统的“一刀切”更准确的哮喘管理方法。虽然挑战,确定治疗的特征”,导致哮喘患者的呼吸道症状可能允许更务实的方法建立更个性化的治疗目标。FootnotesThis手稿最近发表在《欧洲呼吸杂志》上。这里发表周全之前接受的形式排版,我们的生产团队。这些生产过程完成后,作者已经批准结果证明,本文将最新一期的ERJ在线。 Please open or download the PDF to view this article.Conflict of interest: Mario Cazzola participated as a faculty member and advisor in scientific meetings and courses under the sponsorship of Abdi Ibrahim, Alkem, Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, Cipla, GlaxoSmithKline, Glenmark, Lallemand, Mankind Pharma, Menarini Group, Mundipharma, Novartis, Pfizer, Recipharm, Sanofi, Teva, Verona Pharma, and Zambon and is or was a consultant to ABC Farmaceutici, AstraZeneca, Chiesi Farmaceutici, GlaxoSmithKline, Lallemand, Novartis, Ockham Biotech, Recipharm, Verona Pharma, and Zambon.Conflict of interest: Clive p Page has acted as a consultant to Eurodrug, Recipharm, Glycosynnovation and PrEP Biopharma. CPP also holds equity in Verona Pharma.Conflict of interest: Maria Gabriella Matera participated as a faculty member and advisor in scientific meetings and courses under the sponsorship of ABC Farmaceutici, Almirall, AstraZeneca, Chiesi Farmaceutici, GlaxoSmithKline, and Novartis and was a consultant to Chiesi Farmaceutici and GlaxoSmithKline. Her department was funded by GlaxoSmithKline and Novartis.Conflict of interest: Paola Rogliani has participated as a faculty member and advisor in scientific meetings and courses under the sponsorship of Almirall, AstraZeneca, Biofutura, Boehringer Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline, Menarini Group, Mundipharma, Novartis, Recipharm, Sanofi, and Zambon, and her department was funded by Almirall, Boehringer Ingelheim, Chiesi Farmaceutici, Novartis, and Zambon.Conflict of interest: Nicola A. Hanania received honoraria for serving as advisor or consultant for GlaxoSmithKline, AstraZeneca, Sanofi, Regeneron, Amgen, Genentech, Novartis and Teva. His institution received research grant support on his behalf from GlaxoSmithKline, Genentech, Sanofi, Teva, Novartis, and Astra ZenecaConflict of interest: The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in, or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. ER -